Can Regeneron’s Odronextamab Stand Out With Better Safety?
Entering Crowded CD20 Bispecific Field
Presentation of diffuse large B-cell lymphoma data at ASH showed low rates of higher-grade cytokine release syndrome and no cases of ICANS.
![](https://insights.citeline.com/resizer/v2/F33D2J633BKGVNELWZCFEJPGJU.jpg?smart=true&auth=449bbed2e98346982608da617d847f8a7bcdf0d13c02ac70d00d83060469f170&width=700&height=394)
Presentation of diffuse large B-cell lymphoma data at ASH showed low rates of higher-grade cytokine release syndrome and no cases of ICANS.